Connor, Clark & Lunn Investment Management Ltd. Xeris Biopharma Holdings, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 171,332 shares of XERS stock, worth $642,495. This represents 0.0% of its overall portfolio holdings.
Number of Shares
171,332
Previous 83,108
106.16%
Holding current value
$642,495
Previous $236,000
145.76%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding XERS
# of Institutions
163Shares Held
61.5MCall Options Held
34.2KPut Options Held
21.7K-
Black Rock Inc. New York, NY10.3MShares$38.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.9MShares$29.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.35MShares$12.6 Million0.0% of portfolio
-
State Street Corp Boston, MA3.34MShares$12.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.88MShares$10.8 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $510M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...